Close Menu

Gentris

NEW YORK (GenomeWeb) – Cancer Genetics today announced it has signed a non-binding letter of intent to buy Gentris for up to $6.25 million.

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said in its recently filed Form 10-Q that it identified errors in financial statements starting in 2008 through the second quarter of 2013 related to the valuation of finished goods inventory in the company's Life Science segment.

Qlucore has added three new employees to its staff.

Gentris last week expanded its genomic biomarker offering to include Affymetrix GeneChip Human Transcriptome Array services.

NEW YORK (GenomeWeb News) – Nanosphere this week received the CE IVD Mark for its Gram-Negative Blood Culture test that runs on the firm's Verigene molecular diagnostics platform.

NEW YORK (GenomeWeb News) – Idaho Technology has changed its name to BioFire Diagnostics.

NEW YORK (GenomeWeb News) – Becton Dickinson said this week it has declared a quarterly dividend of $45 per share, payable on Sept. 28 to shareholders of record on Sept. 7. The indicated annual dividend rate is $1.80 per share.

Gentris will now offer Affymetrix's DMET Plus as one of its pharmacogenomics services.

NEW YORK (GenomeWeb News) – Gentris and the Shanghai Institutes of Preventative Medicine have signed a memorandum of understanding to collaborate on personalized medicine initiatives.

Pages

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.